NCT02778594View on ClinicalTrials.gov

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Parkinson's Disease (PD)
Interventions
DRUG

BIA 3-202

nebicapone 50 mg tablets; oral use

DRUG

Placebo

Nebicapone matching placebo tablets

DRUG

levodopa 100 mg / benserazide 25 mg

Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use

Trial Locations (1)

4745-457

Human Pharmacology Unit, S. Mamede Do Coronado

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02778594 - Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide | Biotech Hunter | Biotech Hunter